Virtual Meetings 2021

Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

PARTICIPATING FACULTY

Dirk Arnold, MD, PhD
Director
Asklepios Tumorzentrum Hamburg
Asklepios Klinik Altona
Hamburg, Germany

Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Consultant, Mayo Clinic in Arizona
Phoenix, Arizona

Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Daniel Catenacci, MD
Associate Professor, Department of Medicine
Section of Hematology and Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research
Comprehensive Cancer Center
The University of Chicago Medical Center and Biological Sciences
Chicago, Illinois

Kristen K Ciombor, MD, MSCI
Associate Professor of Medicine
Division of Hematology/Oncology
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee



Wells A Messersmith, MD
Professor and Head, Division of Medical Oncology
Associate Director for Translational Research
University of Colorado Cancer Center
Aurora, Colorado

Eileen M O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
Co-Director, Medical Initiatives
David M Rubenstein Center for Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Philip A Philip, MD, PhD, FRCP
Kathryn Cramer Endowed Chair in Cancer Research
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Alan P Venook, MD
The Madden Family Distinguished Professor of
Medical Oncology and Translational Research
Shorenstein Associate Director, Program Development
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Zev Wainberg, MD, MSc
Co-Director, GI Oncology Program
Director of Early Phase Clinical Research
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California


SERIES MODERATOR
Neil Love, MD
Research To Practice
 

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for gastrointestinal cancers. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Selection and Sequencing of Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

    MODULE 2: Evidence-Based Management of Advanced Hepatocellular Carcinoma

    MODULE 3: Optimizing Personalized Treatment for Metastatic Colorectal Cancer

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.

Learning Objectives

  • Evaluate recently presented clinical research findings applicable to the optimal selection and sequencing of systemic therapy for patients with advanced colorectal cancer (CRC), gastric/gastroesophageal cancer (GC) and hepatocellular carcinoma (HCC), and consider how these data sets affect current clinical decision-making.
  • Develop a long-term care plan for patients diagnosed with metastatic CRC, considering biomarker profile (eg, BRAF, microsatellite instability status), tumor location, prior systemic therapy, symptomatology, performance status and personal goals of treatment.
  • Assess biomarker test results (eg, HER2, PD-L1 status), clinical factors and patient preferences to optimize the selection and sequence of systemic therapy for locally advanced or metastatic GC.
  • Use patient age, performance status, degree of liver function and other clinical factors to individualize therapeutic recommendations for newly diagnosed and relapsed/refractory unresectable or metastatic HCC.
  • Appreciate the clinical prevalence and significance of elevated AFP (alpha-fetoprotein) expression in patients with advanced HCC, evaluate available data documenting the benefit of specific management approaches for patients with high AFP levels and personalize therapeutic recommendations.
  • Evaluate the rationale for and appropriateness of specific adaptations to cancer management and follow-up practices for patients with CRC, GC and HCC to account for the realities of the COVID-19 pandemic, and implement or suggest relevant changes within your practice.
  • Appraise available and emerging data with investigational agents and strategies currently in clinical testing for CRC, GC and HCC, and where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Prof Arnold — Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, Lilly, Merck Serono, Roche Laboratories Inc, Samsung Bioepis, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Terumo Medical Corporation; Data and Safety Monitoring Board/Committee: Lilly. Dr Bekaii-Saab — Advisory Committee: Immuneering Corporation, Imugene, Sun Biopharma; Consulting Agreements (to Institution): Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences Inc, Foundation Medicine, Janssen Biotech Inc, Kanaph Therapeutics, Natera Inc, Sobi, Treos Bio, Xilis; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Exelixis Inc, Merck, Pancreatic Cancer Action Network; Inventions/Patents: WO/2018/183488, WO/2019/055687. Dr Bendell — Consulting Agreements (to Institution): Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, a wholly owned subsidiary of Eli Lilly and Company, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Fusion Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Prelude Therapeutics, Relay Therapeutics, Repertoire Immune Medicines, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc; Contracted Research (to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, a wholly owned subsidiary of Eli Lilly and Company, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bellicum Pharmaceuticals Inc, Bicycle Therapeutics, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, CALGB, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Cyteir Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, Hutchison MediPharma, IGM Biosciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Morphotek Inc, Nektar, NeoImmuneTech, NGM Biopharmaceuticals, Novartis, NovoCure Inc, Numab, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, OncXerna Therapeutics Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, PureTech Health, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Repare Therapeutics, Revolution Medicines, Rgenix, Sanofi Genzyme, Scholar Rock, Seagen Inc, Shattuck Labs, Sierra Oncology, Sumitomo Dainippon Pharma Oncology Inc, Stemcentrx, SynDevRx Inc, Synthorx, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tarveda Therapeutics, Tempest Therapeutics, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Transcenta, Treadwell Therapeutics, Tyrogenex, Unum Therapeutics, Vyriad, Zymeworks. Dr Catenacci — Advisory Committee: Astellas, Merck, Seagen Inc, Tempus; Consulting Agreements: Amgen Inc, Archer Pharmaceuticals, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gritstone Oncology, Guardant Health, Lilly, Merck, Natera Inc, Pieris Pharmaceuticals Inc, QED Therapeutics, Seagen Inc, Taiho Oncology Inc, Tempus, Zymeworks; Contracted Research: Amgen Inc, Genentech, a member of the Roche Group; Data and Safety Board: Genentech, a member of the Roche Group, Merck Serono; Speakers Bureau: Genentech, a member of the Roche Group, Guardant Health, Lilly, Merck, Tempus. Dr Ciombor — Consulting Agreements: Merck, Natera Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Incyte Corporation, Merck, NuCana, Pfizer Inc. Dr Messersmith — Contracted Research: ALX Oncology, BeiGene Ltd, Bristol-Myers Squibb Company, Exelixis Inc, Experimental Drug Development Centre (Singapore), Immunomedics Inc, Pfizer Inc, Mitsubishi Tanabe Pharma America; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc, QED Therapeutics, Zymeworks. Dr O’Reilly — Consulting Agreements: Agios Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Berry Genomics, Celgene Corporation, Cend Therapeutics Inc, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Helio Health, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MiNA Therapeutics, QED Therapeutics, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Silenseed Ltd, SillaJen, Sobi, Surface Oncology, TheraBionic, twoXAR Inc, Vector Pharma, Yiviva; Contracted Research: Agios Pharmaceuticals Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioNTech, Bristol-Myers Squibb Company, Celgene Corporation, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Incyte Corporation, Polaris Pharmaceuticals, Puma Biotechnology Inc, QED Therapeutics, SillaJen, Yiviva. Dr Philip — Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Ipsen Biopharmaceuticals Inc, Merck, Merus BV, Novartis, Pfizer Inc, QED Therapeutics, Rafael Pharmaceuticals Inc; Consulting Agreements: Blueprint Medicines, Erytech, IQVIA, Merck, Rafael Pharmaceuticals Inc, SynCore Biotechnology, TriSalus Life Sciences; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biolinx, Bristol-Myers Squibb Company, Celgene Corporation, Corcept Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Five Prime Therapeutics Inc, Forty Seven Inc, Gritstone Oncology, Incyte Corporation, IQVIA, Karyopharm Therapeutics, Merck, Merus BV, Natera Inc, NGM Biopharmaceuticals, Novartis, Novocure Inc, QED Therapeutics, Rafael Pharmaceuticals Inc, SynCore Biotechnology, Taiho Oncology Inc, TriSalus Life Sciences, Tyme Inc; Data and Safety Monitoring Board/Committee: ASLAN Pharmaceuticals, Blueprint Medicines, Erytech; Speakers Bureau: Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Novartis. Dr Venook — Advisory Committee: Amgen Inc, Genentech, a member of the Roche Group, GlaxoSmithKline; Contracted Research: Amgen Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, QED Therapeutics. Dr Wainberg — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Molecular Templates; Contracted Research: Arcus Biosciences, Five Prime Therapeutics Inc, Novartis, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by an educational grant from Lilly.